arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

iBio, Inc.

IBIO
$1.20 ▼ -0.05 (-3.61%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

iBio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC -10.5% ↘
FCF / Share None
Trailing P/E —
Price / Book 0.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 24, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-10.60M
↓ -105.3% —
Operating Margin Operating profit as % of sales
-261.5%
↑ +45.9% —
FCF / Share Free cash flow per share
$-0.05
↑ +12.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
15
Financial Health ↓
6
Cash Quality ↓
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 16 years · 65 quarters